Novel Antitubercular Agents: Design, Synthesis, Molecular Dynamic and Biological Studies of Pyrazole – 1,2,4‐Triazole Conjugates
Chemistry & Biodiversity · 2023
DOI: 10.1002/cbdv.202300971 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2023. Verfasst von K A Ajin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru,…. Hauptthemen laut MEDLINE: Antitubercular Agents, Mycobacterium tuberculosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysore, India, Indian Council for Medical Research, New Delhi.
Abstract (Originalsprache)
Mycobacterium tuberculosis (Mtb) has numerous cell wall and non‐cell wall mediated receptors for drug action, of which cell wall mediated targets were found to be more promising because of their pivotal role in bacterial protection and survival. Herein, we reported the design and synthesis of a series of pyrazole‐linked triazoles based on the reported structural features of promising drug candidates that target DprE1 receptors through a Structure‐based drug design (SBDD) approach ( 6a – 6j and 7a – 7j ). The synthesized compounds were evaluated for their in‐vitro antitubercular activity against virulent strains of Mtb H37Rv. In‐silico studies revealed that most compounds exhibit binding interactions with crucial amino acids like Lys418, Tyr314, Tyr60, and Asp386 at DprE1. Furthermore, the protein‐ligand ( 7j ) shows appreciable stability compared to innate protein in a 100 ns molecular dynamic simulation study. In‐vitro MAB assay revealed that 14 compounds exhibit significant antitubercular activity with minimum inhibitory concentration (MIC) of the 3.15–4.87 μM of the 20 compounds tested. An in‐vitro cytotoxicity study on normal cell lines (MCF10) revealed safe compounds (IC 50 values:341.85 to 726.08 μM). Hence, the present study opens the development of new pyrazole‐linked triazoles as probable DprE1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru, 570015, Karnataka, Indi.
- Department of Microbiology, JSS Medical College, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru, 570015, India.
- Department of Pharmacology, HSK College of Pharmacy, 587101, Bagalkot, India.
ORCID-Profile: Sethu Arun Kumar, Manisha Singh, H S Akshatha, Meduri Bhagyalalitha, Karthik G Pujar, M N Sumana, V M Chandrashekar, Durgesh Bidye, Gurubasavaraj Veeranna Pujar
Förderung
- JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysore, India
- Indian Council for Medical Research, New Delhi
Zitieren
APA
Ajin, K. A., Arun Kumar, S., Singh, M., Akshatha, H. S., Bhagyalalitha, M., Pujar, K. G., Sumana, M. N., Chandrashekar, V. M., Bidye, D., & Pujar, G. V. (2023). Novel Antitubercular Agents: Design, Synthesis, Molecular Dynamic and Biological Studies of Pyrazole – 1,2,4‐Triazole Conjugates. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202300971
Vancouver
Ajin KA, Arun Kumar S, Singh M, Akshatha HS, Bhagyalalitha M, Pujar KG, et al. Novel Antitubercular Agents: Design, Synthesis, Molecular Dynamic and Biological Studies of Pyrazole – 1,2,4‐Triazole Conjugates. Chemistry & Biodiversity. 2023. doi:10.1002/cbdv.202300971
BibTeX
@article{Ajin2023,
author = {Ajin, K A and Arun Kumar, Sethu and Singh, Manisha and Akshatha, H S and Bhagyalalitha, Meduri and Pujar, Karthik G and Sumana, M N and Chandrashekar, V M and Bidye, Durgesh and Pujar, Gurubasavaraj Veeranna},
title = {Novel Antitubercular Agents: Design, Synthesis, Molecular Dynamic and Biological Studies of Pyrazole – 1,2,4‐Triazole Conjugates},
journal = {Chemistry & Biodiversity},
year = {2023},
doi = {10.1002/cbdv.202300971}
}
EUVIMED